

KRT19 Antibody / Cytokeratin 19 [clone Ks19.1] (V2680)


Catalog No.	Formulation	Size
V2680-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2680-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2680SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2680IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml




Citations (10)

[Bulk quote request](#)


Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG2a, lambda
Clone Name	Ks19.1
Purity	Protein G affinity chromatography
UniProt	P08727
Localization	Cytoplasmic
Applications	Western Blot : 1-2ug/10 ⁶ cells Immunofluorescence : 1-2ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
Limitations	This KRT19 antibody is available for research use only.



Immunofluorescent staining of MeOH fixed human MCF7 cells with KRT19 antibody (clone Ks19.1, green) and Reddot nuclear stain (red).



IHC: Formalin-fixed, paraffin-embedded human ovarian carcinoma stained with KRT19 Ab (clone Ks19.1).



Western blot testing of human PC3 cell lysate using KRT19 antibody (clone Ks19.1). Predicted molecular weight ~43 kDa.

Description

This mAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Application Notes

Optimal dilution of the KRT19 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Human breast cancer MCF-7 cells were used as the immunogen for the KRT19 antibody.

Storage

Store the KRT19 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

